Summary

The Trump administration on Wednesday acted to ease access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. Food and Drug Administration scientific staffers had little input on the decision and opposed the changes, according to six people familiar with its development. The draft policy posted online by Kennedy's Department of Health and Human Services covers a handful of injectable peptides promoted within the wellness industry for uses such as building muscle, healing injuries and boosting energy.

AI summaries can be wrong sometimes—always verify important details using the source article.